Jianzhong Zhou

Dr. Jianzhong Zhou


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2024 in Cureus
Verified
Journal Article
Open access
YWYue Wang
Yue Wang
XWXin Wang
Xin Wang
CWChangfen Wang
Changfen Wang
ZZzhou jian zhong
zhou jian zhong
Background Cardiovascular diseases (CVD), including coronary artery disease, ischemic heart disease, stroke, cardiomyopathy, and atrial fibrillation and flutter, are the leading cause of mortality worldwide, resulting in significant economic and health costs. Recognizing trends and geographical differences in the global burden of CVD facilitates health authorities in particular nations to assess the disease burden and forecast future epidemiological trends. Public health authorities in each country can better understand the differences in disease data and, by learning from the experiences and practices of successful countries and considering the characteristics of their diseases, allocate health resources more rationally and formulate more targeted healthcare strategies to reduce the disease burden. This study aims to comprehensively assess CVD trends and geographic variations from 1990 to 2021. Methods This study focuses on analyzing global trends in the epidemiology of all-age CVD incidence and death over the past 30 years. A vital registration system, cause-of-death inference records, and a cause-of-death ensemble model (CODEm) were used to estimate cause-specific mortality for CVD, with CODEm estimates adjusted using a cause-of-death correction (CoDCorrect) algorithm. Incidence data were extracted from insurance claims and inpatient discharge sources and analyzed with Disease Modeling Meta-Regression, Version 2.1 (DisMod-MR 2.1). Data were extracted from the 2021 Global Burden of Disease Study (GBD 2021) on the number of incident cases and deaths, as well as age-standardized incidence rates (ASIR) and age-standardized death rates (ASDR) for CVD for each year from 1990 to 2021. We visualized and reported this data at the global, regional, and national levels. To explore the association between the burden of CVD and sociodemographic factors, we used the sociodemographic index (SDI), which categorizes the world's 204 nations into five SDI regions. Because the GBD results are a combination of data and estimates, 95% uncertainty intervals (UI) are provided for each count and rate (per 100,000 populations). Results Globally, the number of CVD incident cases and deaths increased from 34.74 million and 12.33 million in 1990 to 66.81 million and 19.42 million in 2021, representing a 92.3% and 57.5% rise, respectively. However, the global ASIR and ASDR for CVD have decreased by 10.4% and 34.3%, respectively, since 1990. Notably, among the 21 regions of the world, the ASIR for CVD is on a downward trend from 1990 to 2021, except for East and Central Asia, where the ASIR for CVD increased by 3% and 14.3%, respectively. Similarly, the global ASDR for CVD is only on an upward trend in sub-Saharan Africa, increasing by 12%, while all other regions are on a downward trend. Among the five SDI regions, the high SDI region has much lower ASIR and ASDR compared to the world average, and these rates have decreased significantly over the years. Conclusion Despite a significant increase in the number of CVD incident cases and deaths worldwide over the last three decades, ASIR and ASDR have been declining. Over the past 30 years, both ASIR and ASDR for CVD have declined significantly in high SDI areas, while CVD continues to pose a serious public health threat in regions with low SDI.

19 September 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
LYliu ye
liu ye
CZCheng Zhang
Cheng Zhang
QDQin Duan
Qin Duan
YSYue Shao
Yue Shao
ZZzhou jian zhong
zhou jian zhong
Background: Dietary magnesium and serum magnesium play an important part in cardiovascular disease (CVD). However, the association between magnesium depletion score (MDS) and CVD development and prognosis remains unclear. This analysis examines the cross‐sectional relationship between MDS and CVD, and the longitudinal association between MDS and all‐cause and CVD mortality in individuals with CVD. Methods and Results: In all, 42 711 individuals were selected from the National Health and Nutrition Examination Survey, including 5015 subjects with CVD. The association between MDS and total and individual CVDs was examined using the survey‐weighted multiple logistic regression analysis. Among 5011 patients with CVD, 2285 and 927 participants were recorded with all‐cause and CVD deaths, respectively. We applied survey‐weighted Cox proportional hazards regression analyses to investigate the impact of MDS on the mortality of individuals with CVD. The CVD group had higher MDS levels than the non‐CVD groups. After controlling all confounding factors, individuals with MDS of 2 and ≥3 had higher odds of total CVD and specific CVD than those with MDS of 0. Besides, each 1‐unit increase in MDS was strongly related to the risk of total CVD and specific CVD. The relationship between MDS and total CVD was stable and significant in all subgroups. The fully adjusted Cox regression model indicated that high MDS, irrespective of MDS as a categorical or continuous variable, was significantly associated with an elevated risk of all‐cause and CVD deaths. Conclusions: MDS is a vital risk factor for the prevalence and mortality of individuals with CVD.

25 June 2021 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
JZJianfu Zhu
Jianfu Zhu
XTXiaowei Tan
Xiaowei Tan
ZZzhou jian zhong
zhou jian zhong
Background: Atrial fibrillation (AF) is the most common cardiac rhythm disturbance and leads to morbidity and mortality. Peripheral artery disease (PAD) is associated with atherosclerotic risk factors and always classified as a vascular disease and deemed to be a bad complication of AF. In patients with AF, the risk and prognostic value of PAD have not been estimated comprehensively.Hypothesis: PAD is associated with all‐cause mortality, cardiovascular (CV) mortality, and other outcomes in patients with AF.Methods: We searched PubMed, Embase, and Cochrane Library databases for prospective studies published before April 2021 that provided outcomes data on PAD in confirmed patients with AF. Heterogeneity was estimated using the I2 statistic. The fixed‐effects model was used for low to moderate heterogeneity studies, and the random‐effects model was used for high heterogeneity studies.Results: Eight prospective studies (Newcastle‐Ottawa score range, 7–8) with 39 654 patients were enrolled. We found a significant association between PAD and all‐cause mortality (hazard ratio [HR], 1.42; 95% confidence interval [CI], 1.25–1.62; p < .001), CV mortality (HR, 1.64; 95% CI, 1.32–2.05; p < .001) and MACE (HR, 1.75; 95% CI, 1.38–2.22; p < .001) in patients with AF. No significant relationship was found in major bleeding (HR, 1.22; 95% CI, 0.95–1.57; p = 0.118), myocardial infarction (MI) (HR, 2.07; 95% CI, 1.17–3.67; p = .038), and stroke (HR, 1.14; 95% CI, 0.87–1.50, p = 0.351).Conclusions: PAD is associated with an increased risk of all‐cause mortality, CV mortality, and MACE in patients with AF. However, no significant association was found with major bleeding, MI, and stroke.

1 May 2022 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
XSXueli Shi
Xueli Shi
YWYiping Wang
Yiping Wang
ZZzhou jian zhong
zhou jian zhong
Background: Cancer therapy-related cardiotoxicity has recently become an area of intense research. As the prognostic role of the right ventricle (RV) in a variety of cardiovascular diseases has been confirmed, and several studies have paid increased attention to RV function in cancer patients who have underwent chemotherapy, we provide a meta-analysis to objectively evaluate the mechanical properties of the right ventricular myocardium by echocardiography in this population. Methods: We systematically searched Embase, PubMed, and Cochrane databases were applied to search for studies (published before August 11, 2021) comparing RV contraction measured by echocardiography at baseline to follow-up in cancer patients who underwent chemotherapy or radiotherapy. The mechanical properties of the right ventricular myocardium were pulmonary artery systolic pressure (PASP), tricuspid annular plane systolic excursion (TAPSE), systolic velocity of tricuspid annulus (S'), right ventricular free wall longitudinal strain (RVFWLS), right ventricular global longitudinal strain (RVGLS), and right ventricular fractional area change (RVFAC). We analyzed pooled data using a random-effects model and assessed risk of bias in the included studies using the Newcastle-Ottawa Scale. Results: Twenty-one trials were enrolled (N=1,355 participants). Cancer patients who underwent chemotherapy but not radiotherapy showed an increase in PASP [standardized mean difference (SMD) =0.161, 95% CI: 0.007 to 0.316) compared with the condition at baseline, as well as reductions in TAPSE (SMD =−0.543, 95% CI: −0.698 to −0.389), S' (SMD =−0.507, 95% CI: −0.748 to −0.266), RVFWLS (SMD =0.833, 95% CI: 0.549 to 1.118) and RVGLS (SMD =1.017, 95% CI: 0.751 to 1.283). There was no significant difference in RVFAC (SMD =−0.097, 95% CI: −0.213 to 0.018). Furthermore, these indicators pointed to a deterioration of right ventricular contraction function in cancer patients who underwent chemotherapy and radiotherapy. The risk of bias of the included studies evaluated by the Newcastle-Ottawa Scale was medium to high. Discussion: Right ventricular contraction function would deteriorate in cancer patients who underwent chemotherapy and radiotherapy, especially with the prolongation of chemotherapy duration and accumulation of chemotherapeutic drugs. Further studies are needed to establish the definition of right ventricular systolic dysfunction in clinical practice.


14 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
FLFuwei Liu
Fuwei Liu
JLJun Luo
Jun Luo
PYPENG Yu
PENG Yu
ZZzhou jian zhong
zhou jian zhong
Background: Septic cardiomyopathy (SCM) is a fatal sepsis-induced dysfunction. While Pueraria (Pue) exhibits protective effects in sepsis, its regulatory role regarding programmed cell death (PCD) in SCM remains unclear. This study aimed to identify Pue’s PCD-related targets in SCM and construct a validated diagnostic model. Methods: We analyzed 14 PCD modalities across seven GEO transcriptomic datasets. A robust machine learning framework integrating 171 algorithm combinations built a diagnostic signature. The immune landscape was profiled using single-cell RNA sequencing and enrichment analyses. Experimental validation utilized SCM patient blood samples and heart tissues from an LPS-induced murine model. Results: Nine PCD patterns were significantly altered in SCM. Intersection analysis and machine learning identified five core Pue targets: STAT3, RIPK2, GM2A, ALOX5, and DPP4. A diagnostic model constructed with these genes achieved high AUCs across all datasets. Single-cell analysis revealed cell-type-specific expression within the myocardial immune landscape. Differential expression of these five genes was validated in both human and animal samples, correlating significantly with cardiac function indices. Conclusions: Our results demonstrate that Pueraria mitigates SCM and restores cardiac function by modulating the expression of core PCD-related targets. These targets are closely associated with the localized inflammatory response, providing potential therapeutic avenues for SCM.